US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

DOR

Dor (DOR)

Dor Biopharma

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:DOR

1

Fecha	Hora	Fuente	Título	Símbolo	Compañía
07/04/2006	08:19	Business Wire	DOR BioPharma Announces Advances in Mucosal Vaccines for Botulinum Toxin; Antigens are Made Using Dowpharma's Pfenex Expression	AMEX:DOR	Dor Biopharma
06/04/2006	14:28	Business Wire	DOR BioPharma Announces Private Equity Financing of $3.65 Million with Institutional Investors	AMEX:DOR	Dor Biopharma
30/03/2006	08:00	Business Wire	DOR BioPharma Reports Year End 2005 Financial Results and Accomplishments; DOR Provides Guidance on Regulatory Filings on orBec	AMEX:DOR	Dor Biopharma
08/02/2006	08:25	Business Wire	DOR BioPharma Provides Financial Guidance and Update on European Regulatory Plans for orBec(R)	AMEX:DOR	Dor Biopharma
30/01/2006	16:48	Business Wire	DOR BioPharma Announces Positive Phase I Results of RiVax(TM), its Vaccine Against Ricin Toxin; Vaccine is Immunogenic and Well	AMEX:DOR	Dor Biopharma
25/01/2006	09:31	Business Wire	DOR BioPharma Achieves Manufacturing Milestone in Development of RiVax(TM); DOR and Its Collaborators Achieve 2nd Milestone Ahea	AMEX:DOR	Dor Biopharma
20/01/2006	07:10	Business Wire	DOR BioPharma Reports Positive New Survival Findings from Previously Completed Phase II and III Clinical Trials of orBec(R); Res	AMEX:DOR	Dor Biopharma
19/01/2006	08:26	Business Wire	DOR BioPharma Secures $6 Million Equity Commitment from Fusion Capital	AMEX:DOR	Dor Biopharma
15/11/2005	08:04	Business Wire	DOR BioPharma Plans FDA NDA and European MAA Filing Strategy for orBec	AMEX:DOR	Dor Biopharma
14/11/2005	15:26	Business Wire	DOR BioPharma Inc. Reports Third Quarter 2005 Financial Results and Reviews Recent Achievements; Conference Call Scheduled for N	AMEX:DOR	Dor Biopharma
07/11/2005	06:00	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference	AMEX:DOR	Dor Biopharma
02/11/2005	05:00	Business Wire	DOR BioPharma Executes Letter of Intent for Acquisition of Gastrotech Pharma; Acquisition Bolsters Biotherapeutics Pipeline	AMEX:DOR	Dor Biopharma
01/11/2005	15:34	Business Wire	DOR BioPharma Receives Notice of Delisting from American Stock Exchange; Company to Continue to Negotiate Potential Compliance-A	AMEX:DOR	Dor Biopharma
14/10/2005	08:17	Business Wire	DOR BioPharma Provides Update on Programs and Corporate Matters	AMEX:DOR	Dor Biopharma
15/09/2005	16:41	PR Newswire (US)	Dr. Chris Dale, Vice President, Technology, Cambrex Biopharmaceuticals and Dr. Robert N. Brey, Chief Scientific Officer, DOR Bio	AMEX:DOR	Dor Biopharma
26/07/2005	12:07	PR Newswire (US)	DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC(TM), DOR's Oral Vaccine Against Botulinum Toxin	AMEX:DOR	Dor Biopharma
15/06/2005	05:30	Business Wire	DOR BioPharma, Inc. Announces Positive Interim Results from Phase I Clinical Trial of RiVax, Its Ricin Toxin Vaccine	AMEX:DOR	Dor Biopharma
13/06/2005	10:14	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd Annual Security and Connectivity Conference	AMEX:DOR	Dor Biopharma
04/05/2005	09:51	Business Wire	DOR BioPharma to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference	AMEX:DOR	Dor Biopharma
04/05/2005	07:30	Business Wire	DOR BioPharma Appoints T. Jerome Madison to Board of Directors	AMEX:DOR	Dor Biopharma
07/01/2005	07:30	PR Newswire (US)	DOR BioPharma and Cambrex Enter into a Development and Manufacturing Process Agreement for RiVax(TM)	AMEX:DOR	Dor Biopharma

Showing the most relevant articles for your search:AMEX:DOR

1

BNP Paribas Issuance

Brent Crude Mro

Hochschild Mining (QX)

NLBNPIT201I2 20351221 25...

Spdr Ftal(dist)

Bnp Paribas Issuance

Natixis Structured Issua...

Vontobel Financial Produ...

Leverage Shares 3X PLTR

WisdomTree Issuer ICAV

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones